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CLINICAL EXPERIENCES WITH METHOXSALEN IN THE TREATMENT OF
VITILIGO
JOSEPH A. ELLIOTT, JR., M.D.
Charlotte, North Carolina
Stimulated by reports in the literature on the
treatment of vitiligo with psoralens (1—6) and
by the inadequacies and dangers of gold salts
then being used, a study was initiated in 1954
to determine first hand the effectiveness of oral
administration of methoxsalen to individuals
with vitiligo concomitant with exposure of the
vitiliginous skin to sunshine. The results of the
first two years of this study were reported in
1956 (7).
This report covers a four year period based on
the treatment of 27 cases of vitiligo for a period
of from 1 to 32 months. The period evaluated
consisted of about 290 patient-months. Twenty
of the patients were female and seven male,
ranging in age from eight to 55 years with a mean
age of 34 years. Duration of the depigmentation
prior to treatment varied from one month to 25
years. In four cases the duration was less than
six months and in another four cases greater than
20 years when treatment was initiated. The
duration was greater than seven years in 50 per
cent of the cases. Nine patients were less than 15
years old (the youngest was six) and seven were
more than 40 years of age (the oldest was 53)
at the time of onset of depigmentation. The mean
age was 26. The sites of affliction were the hands
(82 per cent), body and face (50 per cent each)
and after these, the axillas, upper extremities,
feet, lower extremities and genital areas. Forty-
one per cent of the patients gave a positive family
history for vitiligo.
Five of the patients were treated for four
months in the summer of 1954 and for varying
lengths of time subsequently. One of these has
continued treatment up until the present, except
for nine months during a pregnancy in 1957, for
a total of 30 months' treatment. The remaining
22 patients were treated for periods varying from
134 to 32 months between January, 1955 and
January, 1958. Twelve of the 27 patients are
Presented at the Brook Lodge Invitational
Symposium on the Psoralens, sponsored by The
Upjohn Company, Kalamazoo, Michigan, March
27—28, 1958.
311
still being treated. The others discontinued treat-
ment for various reasons which include: unsatis-
factory results, lack of time for adequate exposure
to sunlight, nausea and vomiting, abnormal
serum bromsulphalein retention, an article ap-
pearing in "Today's Health", fear of injections,
cost of treatment, drudgery of exposure to sun-
light, itching after exposure to sunlight, "moved
to another state" and vitiligo "well". The average
duration of administration in those who stopped
was seven months; three had treatment for less
than four months. Those patients continuing
therapy averaged 17 months' treatment with
only two patients receiving less than ten months'
treatment. Four have had treatment for more
than 24 months and eight for more than 12
months.
Treatment during the summer of 1954 con-
sisted of: (1) 10 mg. methoxsalen given orally
three times a day after meals; (2) exposure of
the depigmented areas to sunlight at noon each
day, increasing the time of exposure as tolerated;
(3) avoidance of foods with a high vitamin C
content (oranges, grapefruit, peaches, tomatoes
and cabbage). Throughout this period of study
clinical laboratory studies consisting of routine
urinalyses, complete blood counts, tests for
urinary porphyrins, prothrombin times and
cephalin-cholesterol flocculation tests were made.
Treatment during the remaining period of
study consisted of: (1) 20 mg. methoxsalen given
daily two hours before exposure to ultraviolet
light; (2) exposure of the depigmented areas to
sunlight at noon each day (in the winter or when
sunlight was not available, some of the patients
used a General Electric R.S. Sunlamp), increasing
the time of exposure as tolerated. Throughout
this period of study, either eephalin-cholesterol
flocculation tests or serum bromsulphalein tests*
were made.
* Five mg. of bromsulphalein per kg. body
weight was injected intravenously; the serum
content of the dye was then determined 45 minutes
later. More than five per cent retention is con-
sidered indicative of liver damage.
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RESULTS
In no instance was the vitiligo cured, although
seven patients had complete repigmentation of
selected areas. Five patients showed no appre-
ciable repigmentation or tanning, suggesting
inadequate exposure to sunlight. All of the pa-
tients who followed the treatment regimen ade-
quately to obtain satisfactory tanning of the nor-
mal skin showed significant repigmentation of
the vitiliginous skin.
It was felt more practical to classify the results
of treatment as satisfactory or unsatisfactory
on the basis of the patient's evaluation of the
cosmetic result, since it is difficult and inadequate
to evaluate the result on the basis of percentage
repigmentation, and obtaining a cosmetically
acceptable result is the reason for treatment.
Eighteen of the patients receiving treatment felt
that the result was satisfactory and nine felt
that it was unsatisfactory. One patient in evalu-
ating her result stated that previously she would
not go to Sunday school or church because of
the appearance of her skin, but now her degree of
improvement is such that she can go. Only one
Negro was in this group. She repigmcnted more
rapidly than expected, by comparison with the
other patients.
In general the amount of repigmentation
seemed to be more dependent on the total time
of exposure to sunlight and the location of the
lesion than on the age of the patient, duration of
the disease or the extent of involvement. The
dorsum of the hands and feet showed less repig-
mentation than lesions over fleshy areas such as
the face, abdomen or axillas. Repigmcntation
took place as a perifollicular pigmentation which
enlarged to coalesce into solid patches, usually
darker than the surrounding "normal" skin.
There was some loss of the newly acquired
pigment during the interim in which no treat-
ment was given. This loss could apparently be
prevented by continued treatment with methox-
salen and use of a General Electric R.S. Sunlamp
when exposure to sunlight was not practical.
However, there was no significant gain in new
pigment with use of this artificial ultraviolet
light source.
Throughout the period of study all clinical
laboratory study results were negative except
for the cephalin-cholesterol flocculation and
serum bromsulphalein tests. The ccphalin-
cholesterol flocculation test was always negative
at 24 hours with one exception when it was 3+
at both 24 hours and 48 hours on serum taken
from a patient before treatment was begun, and
in this patient despite treatment with methox-
salea a serum bromsulphaleia test showed only
a very faint trace one month later. Because the
cephaliu-cholesterol flocculation test was fre-
quently and irregularly positive and thus difficult
to interpret it was discontinued in early 1955
and the serum bromsulphalein test used there-
after. One patient's cephalin-cholcsterol floccu-
lation test became 2 + at 48 hours after three
months' treatment with methoxsalen in 1954
and was 3+ at 48 hours when treatment was
resumed in the spring of 1955. A month later
the serum bromsulphalein test showed five per
cent retention, the following month it was ten
per cent and the third month 20 per cent. Un-
fortunately a serum bilirubin test was not done,
even though there was no clinical evidence of
jaundice. The patient complained of extreme
fatigue but otherwise was asymptomatic. Treat-
ment with methoxsalen was discontinued. Eleven
months later the serum bromsulphalcin test still
showed 14 per cent retention. In another ease
the pre-treatment cephalin-cholesterol floccula-
tion test was 1+ at 48 hours. After one month's
treatment with methoxsalcn the serum brom-
sulphalein test showed "less than eight per cent
retention". The following month with continued
treatment it was six per cent and after the third
month of treatment ten per cent. rrreatment was
stopped. Although there was no clinical evidence
of jaundice, the patient complained of fatigue. A
third patient had a serum bromsulphalein reten-
tion of eight per cent before treatment with
methoxsalen. There was no change in four subse-
quent serum bromsulphalein tests over a period
of nine months during which the patient received
20 mg. of methoxsalen daily. One hundred sixty-
six serum bromsulphalein tests on the remaining
24 patients were all negative.
One nine year old patient stopped treatment
because of nausea and vomiting each time the
capsules were taken. Four patients complained
of severe itching after exposure to sunlight while
taking methoxsalen. Two of these developed a
polymorphous light eruption which has contin-
ued to recur with exposure to sunlight although
neither has taken any methoxsalen for more than
two years. Four patients developed hypcrtricho-
sis, one getting a regrowth of pigmented hair in
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an area of vitiligo on the dorsum of the hands. In
each instance the hypertrichosis was transient,
disappearing at the end of the summer. Five
patients had increased tension or insomnia,
although minor, and one mild rhinitis.
sUMMARY AND CONCLUSIONS
Although no patient was cured of his vitiligo,
67 per cent felt that the results justified the cost
of treatment and the time expended. The con-
tinued repigmentation with prolonged treatment
would suggest that 100 per cent repigmentation
could be obtained if treatment were continued
long enough with sufficient intensity.
In general, the amount of repigmentation
seemed to be more dependent on the total time
of exposure to sunlight and the location of the
lesion than on the age of the patient, duration of
the disease or the extent of involvement. The
dorsum of the hands and feet repigmented much
less readily than other areas.
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